Department of Internal Medicine B and the Rheumatology Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Department of Internal Medicine F and the Rheumatology Unit, The Chaim Sheba Medical Center, Ramat Gan, Israel.
Int J Rheum Dis. 2019 May;22(5):940-945. doi: 10.1111/1756-185X.13483. Epub 2019 Feb 6.
Anti-neutrophil cytoplasmic antibodies (ANCA) have a role in the diagnostic workup of ANCA-associated vasculitis. However, the clinical significance of positive ANCA in the absence of vasculitis is yet to be determined. Therefore, we sought to investigate the clinical spectrum and rate of patients with a positive ANCA without evidence of vasculitis.
Retrospective analysis of patients positive for cytoplasmic ANCA (C-ANCA) and proteinase 3 (PR3) or P-ANCA and myeloperoxidase (MPO) between 2007 and 2016 in the Chaim Sheba Medical Center, Israel. The proportion of patients who had no evidence of vasculitis among all patients with a positive C-ANCA/PR3 or P-ANCA/MPO was calculated according to tertiles of enzyme-linked immunosorbent assay (ELISA) antibody levels.
Among 113 patients who tested positive for C-ANCA/PR3 or P-ANCA/MPO, 68 (60.1%) had no evidence of vasculitis. ELISA antibody titers were significantly higher among patients with vasculitis than those without (6.2 vs 3.2, for C-ANCA/PR3 and 5.4 vs 2.6 for P-ANCA/MPO, P < 0.05). The proportion of patients without vasculitis among all patients with a positive C-ANCA/PR3 and among all patients with a positive P-ANCA/MPO declined in parallel to the increases in ELISA antibody level tertiles (96%, 57% and 22% in the 1st, 2nd and highest tertiles, respectively, for patients with C-ANCA/PR3 patients and 100%, 66% and 20% in the 1st, 2nd and highest tertiles, respectively, for patients with P-ANCA/MPO).
A significant proportion of patients with a positive C-ANCA/PR3 or P-ANCA/MPO do not have evidence of vasculitis, particularly those with low-medium ELISA antibody titers. Using a higher threshold of ANCA titers may be required to improve specificity.
抗中性粒细胞胞浆抗体(ANCA)在 ANCA 相关性血管炎的诊断中起作用。然而,在没有血管炎的情况下,阳性 ANCA 的临床意义尚待确定。因此,我们旨在研究在没有血管炎证据的情况下,具有阳性 ANCA 的患者的临床谱和比率。
对 2007 年至 2016 年间在以色列 Chaim Sheba 医疗中心检测到细胞质 ANCA(C-ANCA)和蛋白酶 3(PR3)或 P-ANCA 和髓过氧化物酶(MPO)阳性的患者进行回顾性分析。根据酶联免疫吸附试验(ELISA)抗体水平的三分位数,计算所有 C-ANCA/PR3 或 P-ANCA/MPO 阳性患者中无血管炎证据的患者比例。
在 113 例 C-ANCA/PR3 或 P-ANCA/MPO 阳性患者中,68 例(60.1%)无血管炎证据。血管炎患者的 ELISA 抗体滴度明显高于无血管炎患者(C-ANCA/PR3 为 6.2 对 3.2,P-ANCA/MPO 为 5.4 对 2.6,P<0.05)。在所有 C-ANCA/PR3 阳性患者和所有 P-ANCA/MPO 阳性患者中,无血管炎患者的比例与 ELISA 抗体水平三分位数的增加呈平行下降趋势(C-ANCA/PR3 患者第 1、2 和最高三分位组分别为 96%、57%和 22%,P-ANCA/MPO 患者分别为 100%、66%和 20%)。
相当一部分 C-ANCA/PR3 或 P-ANCA/MPO 阳性患者没有血管炎证据,特别是那些 ELISA 抗体滴度较低的患者。使用更高的 ANCA 滴度阈值可能有助于提高特异性。